Laboratorios Farmaceúticos Rovi SA (LABFF)
65.86
0.00 (0.00%)
USD |
OTCM |
Jun 10, 16:00
Laboratorios Farmaceúticos Rovi Enterprise Value : 3.403B for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 3.403B |
| June 09, 2026 | 3.403B |
| June 08, 2026 | 3.403B |
| June 05, 2026 | 3.403B |
| June 04, 2026 | 3.403B |
| June 03, 2026 | 3.403B |
| June 02, 2026 | 3.403B |
| June 01, 2026 | 3.403B |
| May 29, 2026 | 3.403B |
| May 28, 2026 | 3.403B |
| May 27, 2026 | 3.403B |
| May 26, 2026 | 3.403B |
| May 22, 2026 | 3.403B |
| May 21, 2026 | 3.403B |
| May 20, 2026 | 3.403B |
| May 19, 2026 | 3.403B |
| May 18, 2026 | 3.403B |
| May 15, 2026 | 3.403B |
| May 14, 2026 | 3.403B |
| May 13, 2026 | 3.403B |
| May 12, 2026 | 3.403B |
| May 11, 2026 | 3.403B |
| May 08, 2026 | 3.403B |
| May 07, 2026 | 3.403B |
| May 06, 2026 | 3.403B |
| Date | Value |
|---|---|
| May 05, 2026 | 3.403B |
| May 04, 2026 | 3.403B |
| May 01, 2026 | 3.403B |
| April 30, 2026 | 3.403B |
| April 29, 2026 | 3.403B |
| April 28, 2026 | 3.403B |
| April 27, 2026 | 4.669B |
| April 24, 2026 | 3.403B |
| April 23, 2026 | 3.403B |
| April 22, 2026 | 3.403B |
| April 21, 2026 | 3.403B |
| April 20, 2026 | 3.403B |
| April 17, 2026 | 3.403B |
| April 16, 2026 | 3.403B |
| April 15, 2026 | 3.403B |
| April 14, 2026 | 3.403B |
| April 13, 2026 | 3.403B |
| April 10, 2026 | 3.403B |
| April 09, 2026 | 3.403B |
| April 08, 2026 | 3.403B |
| April 07, 2026 | 3.403B |
| April 06, 2026 | 3.403B |
| April 02, 2026 | 3.403B |
| April 01, 2026 | 3.403B |
| March 31, 2026 | 3.403B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Almirall SA | 3.086B |
| AstraZeneca PLC | 581.37B |
| ANI Pharmaceuticals, Inc. | 2.161B |
| Corcept Therapeutics, Inc. | 8.056B |
| Assertio Holdings, Inc. | 120.08M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 11.05M |
| Revenue (Quarterly) | 178.41M |
| Total Expenses (Quarterly) | 167.32M |
| EPS Diluted (Quarterly) | 0.2168 |
| Gross Profit Margin (Quarterly) | 55.56% |
| Profit Margin (Quarterly) | 6.20% |
| Earnings Yield | 4.54% |
| Operating Earnings Yield | 5.52% |
| Normalized Earnings Yield | 4.541 |